Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
How do you treat front line de novo HER2 positive metastatic breast cancer with brain metastases?
Related Questions
In what situations would you consider doublet chemotherapy in treatment of a premenopausal de novo metastatic TNBC?
Is there a correlation with severity of rash as an adverse event and response rate with capivasertib?
In what circumstance, if any, would you consider fulvestrant + capivasertib over CDK4/6 inhibitors in a patient who has HR+, PIK3CA mutant metastatic breast cancer?
Is there any data to use PIK3CA directed agents in mutated metastatic triple negative breast cancer?
How, if at all, do you use changes in SUV on a PET-CT to assess for disease progression/response in patients with metastatic breast cancer?
What are your top takeaways in Breast Cancer from ESMO 2024?
How do you treat metastatic adenoid cystic carcinoma of breast primary, ER 3%, PR, HER 2 negative with liver only metastasis?
Do you routinely check echocardiograms on all patients who are starting TDM1?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
Do you use elacestrant for all patients with metastatic ER+, HER2-, ESR1 mutated breast cancer regardless of duration of response to prior ET+CDK4/6i?
